Soleno Therapeutics에 대한 매도 수량은 투자자에게 Soleno Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Soleno Therapeutics (NASDAQ:SLNO) 주식, 공매도 수량 보고

Soleno Therapeutics

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Biotech

Equities

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Market Summary

Mid Cap

Health Care

Small Cap

Tech

$BTC

AVGO

CVNA

MSTR

NVDA

SLNO

TSLA

VERA

엔비디아(NASDAQ:NVDA)는 지난 1년간 수익률 순위에서 나스닥 100 지수 1위를 차지하며 눈에 띄는 기술 주식이었다.
이 칩 제조업의 거인은 인공지능(AI) 개발을 위한 칩에 대한 급증하는 수요로, 지난 2023년 5월 말 이후 무려 186%나 급등했다.

엔비디아는 1년 전 대비 186% 상승했지만, 다음의 7개 주식은 이보다 두 배 이상의 수익 기록

Soleno Therapeutics Inc

<p><strong>Moderna Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares closed up Thursday gaining momentum following recent comments by Oracle Chairman <strong>Larry Ellison</strong> about the role of artificial intelligence in<a href="https://www.benzinga.com/general/health-care/25/01/43145442/moderna-shares-are-up-today-whats-going-on"> revolutionizing cancer treatment.</a></p>
<p><strong>What To Know: </strong>Ellison, speaking at a White House event, highlighted AI&#8217;s potential to analyze blood tests for early cancer detection, identify tumor fragments and sequence cancer genes to create personalized mRNA vaccines. He claimed AI-driven automation could enable the production of these vaccines within 48 hours, significantly expediting personalized treatment.</p>
<p>The remarks were made as part of the announcement of Stargate, a $500 billion private-sector initiative led by OpenAI, SoftBank and Oracle to develop large-scale AI infrastructure in the U.S. President <strong>Donald Trump </strong>emphasized the project&#8217;s significance in advancing AI capabilities and creating over 100,000 jobs.</p>
<p>The initiative includes the construction of 20 massive data centers, with the first already underway in Texas. These facilities will support AI applications in healthcare, including electronic health record analysis and advanced diagnostics.</p>
<p><strong>MRNA Price Action:</strong> Moderna shares closed Thursday up 10.10% at $42.39, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="527" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23161919/Screenshot-2025-01-23-at-16.18.45-1024x527.png" alt="" class="wp-image-747744" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23161919/Screenshot-2025-01-23-at-16.18.45-1024x527.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23161919/Screenshot-2025-01-23-at-16.18.45-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23161919/Screenshot-2025-01-23-at-16.18.45-768x395.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23161919/Screenshot-2025-01-23-at-16.18.45.png 1393w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/etfs/specialty-etfs/25/01/43160029/tesla-nvidia-etfs-in-the-works-to-tap-rising-interest-in-same-day-stock-options">Tesla, Nvidia ETFs In The Works To Tap Rising Interest In Same-Day Stock Options</a></strong></li>
</ul>
<p><em>Photo: Shutterstock.</em></p>


News

Movers

MRNA

Moderna Shares Are Up Today: What's Going On?

<p>USCB Financial Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USCB#NASDAQ">USCB</a>) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.36 by 5.56 percent. This is a 100 percent increase over earnings of $0.17 per share from the same period last year.  The company reported quarterly sales of $22.98 million which beat the analyst consensus estimate of $22.41 million by 2.57 percent.  This is a 46.38 percent increase over sales of $15.70 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

USCB

USCB Financial Holdings Q4 Adj $0.34 Misses $0.36 Estimate, Sales $22.98M Beat $22.41M Estimate

<p>The earnings results for <strong>CSX</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) for Q4 were made public on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>CSX missed estimated earnings by 0.0%, reporting an EPS of $0.42 versus an estimate of $0.42.</p>
<p>Revenue was down $140.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed on EPS by $0.02 which was followed by a 7.000000000000001% drop in the share price the next day.</p>
<p>Here's a look at CSX's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.48</td>
<td>0.48</td>
<td>0.45</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.46</td>
<td>0.49</td>
<td>0.46</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.67B</td>
<td>3.70B</td>
<td>3.66B</td>
<td>3.63B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.62B</td>
<td>3.70B</td>
<td>3.68B</td>
<td>3.68B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for CSX <a href="https://www.benzinga.com/quote/CSX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CSX: Q4 Earnings Insights

<p><strong>Business First Bancshares</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFST#NASDAQ">BFST</a>) announced its Q4 earnings on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Business First Bancshares beat estimated earnings by 35.0%, reporting an EPS of $0.66 versus an estimate of $0.49.</p>
<p>Revenue was up $17.41 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.11, leading to a 4.0% increase share price change the next day.</p>
<p>Here's a look at Business First Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.57</td>
<td>0.51</td>
<td>0.57</td>
<td>0.60</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.68</td>
<td>0.64</td>
<td>0.50</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>65.32M</td>
<td>62.96M</td>
<td>62.22M</td>
<td>62.47M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>66.90M</td>
<td>66.19M</td>
<td>60.92M</td>
<td>60.17M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Business First Bancshares <a href="https://www.benzinga.com/quote/BFST/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BFST

Earnings Summary: Business First Bancshares Q4

<p>The earnings results for <strong>Covenant Logistics Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVLG#NYSE">CVLG</a>) for Q4 were made public on Thursday, January 23, 2025 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Covenant Logistics Gr missed estimated earnings by 0.0%, reporting an EPS of $0.49 versus an estimate of $0.49.</p>
<p>Revenue was up $3.35 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company missed on EPS by $0.0 in the previous quarter, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Covenant Logistics Gr's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.55</td>
<td>0.49</td>
<td>0.39</td>
<td>0.52</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.55</td>
<td>0.52</td>
<td>0.42</td>
<td>0.54</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>299.81M</td>
<td>292.63M</td>
<td>273.30M</td>
<td>281.75M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>258.60M</td>
<td>287.50M</td>
<td>278.76M</td>
<td>273.99M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Covenant Logistics Gr <a href="https://www.benzinga.com/quote/CVLG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CVLG

Recap: Covenant Logistics Gr Q4 Earnings

<p><strong>East West Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) released its Q4 earnings on Thursday, January 23, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>East West Bancorp missed estimated earnings by -2.0%, reporting an EPS of $2.08 versus an estimate of $2.12.</p>
<p>Revenue was up $12.79 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 6.0% increase share price change the next day.</p>
<p>Here's a look at East West Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.06</td>
<td>1.97</td>
<td>2</td>
<td>1.89</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.09</td>
<td>2.07</td>
<td>2.08</td>
<td>2.02</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>561.26M</td>
<td>554.96M</td>
<td>581.10M</td>
<td>576.55M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>572.72M</td>
<td>553.23M</td>
<td>565.14M</td>
<td>574.83M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for East West Bancorp <a href="https://www.benzinga.com/quote/EWBC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EWBC

Earnings Breakdown: East West Bancorp Q4

<p><strong>SouthState</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) released its Q4 earnings on Thursday, January 23, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>SouthState beat estimated earnings by 12.0%, reporting an EPS of $1.93 versus an estimate of $1.72.</p>
<p>Revenue was up $30.60 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.26 in the last quarter, resulting in a 1.0% increase share price change the following day.</p>
<p>Here's a look at SouthState's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.64</td>
<td>1.54</td>
<td>1.55</td>
<td>1.54</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.90</td>
<td>1.79</td>
<td>1.58</td>
<td>1.67</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>429.33M</td>
<td>418.08M</td>
<td>414.33M</td>
<td>417.72M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>426.41M</td>
<td>425.48M</td>
<td>415.49M</td>
<td>419.72M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for SouthState <a href="https://www.benzinga.com/quote/SSB/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: SouthState Q4

<p>The earnings results for <strong>OceanFirst Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCFC#NASDAQ">OCFC</a>) for Q4 were made public on Thursday, January 23, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>OceanFirst Financial beat estimated earnings by 3.0%, reporting an EPS of $0.38 versus an estimate of $0.37.</p>
<p>Revenue was down $4.50 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company beat on EPS by $0.01, resulting in a 2.0% drop change in the share price the following day.</p>
<p>Here's a look at OceanFirst Financial's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.38</td>
<td>0.43</td>
<td>0.41</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.39</td>
<td>0.39</td>
<td>0.44</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>83.18M</td>
<td>85.46M</td>
<td>87.40M</td>
<td>90.36M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>82.22M</td>
<td>82.26M</td>
<td>86.22M</td>
<td>87.82M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for OceanFirst Financial <a href="https://www.benzinga.com/quote/OCFC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OCFC

OceanFirst Financial Earnings Analysis: Q4 Recap

<p><strong>Byline Bancorp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BY#NYSE">BY</a>) announced its Q4 earnings on Thursday, January 23, 2025 at 04:15 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Byline Bancorp beat estimated earnings by 13.0%, reporting an EPS of $0.69 versus an estimate of $0.61.</p>
<p>Revenue was up $3.88 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.05 which was followed by a 1.0% increase in the share price the next day.</p>
<p>Here's a look at Byline Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.65</td>
<td>0.63</td>
<td>0.63</td>
<td>0.67</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.70</td>
<td>0.68</td>
<td>0.70</td>
<td>0.73</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>101.08M</td>
<td>99.23M</td>
<td>98.06M</td>
<td>101.40M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>101.84M</td>
<td>99.37M</td>
<td>101.01M</td>
<td>100.79M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Byline Bancorp <a href="https://www.benzinga.com/quote/BY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Byline Bancorp Q4 Earnings Assessment

<p><strong>SB Finl Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFG#NASDAQ">SBFG</a>) just disclosed its Q4 earnings on Thursday, January 23, 2025 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>SB Finl Gr beat estimated earnings by 27.0%, reporting an EPS of $0.52 versus an estimate of $0.41.</p>
<p>Revenue was up $339 thousand from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed on EPS by $0.01 which was followed by a 6.0% drop in the share price the next day.</p>
<p>Here's a look at SB Finl Gr's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.42</td>
<td>0.35</td>
<td>0.30</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.41</td>
<td>0.46</td>
<td>0.33</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>9.70M</td>
<td>9.40M</td>
<td>9.50M</td>
<td>9.40M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>14.31M</td>
<td>14.04M</td>
<td>13.13M</td>
<td>15.12M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for SB Finl Gr <a href="https://www.benzinga.com/quote/SBFG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SBFG

SB Finl Gr Earnings Report: Q4 Overview

<p>OP Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPBK#NASDAQ">OPBK</a>) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $0.36 by 8.33 percent. This is a 2.94 percent decrease over earnings of $0.34 per share from the same period last year.</p>


OPBK

OP Bancorp Q4 EPS $0.33 Misses $0.36 Estimate

<p><strong>Customers Bancorp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBI#NYSE">CUBI</a>) reported its Q4 earnings results on Thursday, January 23, 2025 at 04:30 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Customers Bancorp beat estimated earnings by 13.0%, reporting an EPS of $1.36 versus an estimate of $1.2.</p>
<p>Revenue was down $4.68 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>In the previous quarter, the company missed on EPS by $0.09, resulting in a 1.0% drop change in the share price the following day.</p>
<p>Here's a look at Customers Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.43</td>
<td>1.43</td>
<td>1.63</td>
<td>1.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.34</td>
<td>1.49</td>
<td>1.42</td>
<td>1.90</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>170.12M</td>
<td>164.48M</td>
<td>167.86M</td>
<td>173.26M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>158.54M</td>
<td>167.65M</td>
<td>160.38M</td>
<td>172.51M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Customers Bancorp <a href="https://www.benzinga.com/quote/CUBI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CUBI

Customers Bancorp Earnings Report: Q4 Overview

<p>The KC-46A program pre-tax charge of $0.8 billion reflects higher estimated manufacturing costs, including impacts of the IAM work stoppage and agreement.&nbsp;</p>
<p>The T-7A program pre-tax charge of $0.5 billion was primarily driven by higher estimated costs on production lots in 2026 and beyond. Defense, Space &amp; Security expects to report fourth quarter revenue of $5.4 billion and operating margin of (41.9) percent.</p>


Guidance

Boeing Expects Defense, Space & Security To Recognize Pre-tax Earnings Charges Of $1.7B On KC-46A, T-7A, Commercial Crew, VC-25B, and MQ-25 Programs

WIIM

Boeing shares are trading lower after the company reported preliminary Q4 financial results.

Five Point Holdings shares are trading higher after the company reported a year-over-year increase in Q4 financial results.

<p>Commercial Airplanes results will reflect impacts associated with the IAM work stoppage and agreement including lower deliveries and pre-tax earnings charges of $1.1 billion on the 777X and 767 programs.&nbsp;</p>
<p>The 777X program pre-tax charge of $0.9 billion reflects higher estimated labor costs associated with finalizing the IAM agreement and will be incurred over the next several years. The company still anticipates first delivery of the 777-9 in 2026.</p>


Boeing Expects Commercial Airplanes To Report Q4 Revenue Of $4.8B And Operating Margin Of (43.9)%; Still Anticipates First Delivery Of The 777-9 In 2026

<p>The Q4 earnings report for <strong>Columbia Banking System</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) was released on Thursday, January 23, 2025 at 04:02 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Columbia Banking System beat estimated earnings by 9.0%, reporting an EPS of $0.71 versus an estimate of $0.65.</p>
<p>Revenue was down $32.04 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company beat on EPS by $0.07 in the last quarter, resulting in a 1.0% drop share price change the following day.</p>
<p>Here's a look at Columbia Banking System's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.62</td>
<td>0.57</td>
<td>0.53</td>
<td>0.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.69</td>
<td>0.67</td>
<td>0.65</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>481.03M</td>
<td>475.95M</td>
<td>480.36M</td>
<td>526.68M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>496.38M</td>
<td>472.15M</td>
<td>473.72M</td>
<td>519.16M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Columbia Banking System <a href="https://www.benzinga.com/quote/COLB/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


COLB

Columbia Banking System Earnings Report: Q4 Overview

<p><strong>Texas Instruments</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) released its Q4 earnings on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Texas Instruments beat estimated earnings by 8.0%, reporting an EPS of $1.3 versus an estimate of $1.2.</p>
<p>Revenue was down $70.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company beat on EPS by $0.09, resulting in a 4.0% increase change in the share price the following day.</p>
<p>Here's a look at Texas Instruments's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.38</td>
<td>1.17</td>
<td>1.07</td>
<td>1.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.47</td>
<td>1.22</td>
<td>1.20</td>
<td>1.49</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>4.12B</td>
<td>3.82B</td>
<td>3.61B</td>
<td>4.12B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>4.15B</td>
<td>3.82B</td>
<td>3.66B</td>
<td>4.08B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Texas Instruments management provided guidance for Q1 2025, expecting earnings between $0.94 and $1.16 per share.</p>
<p>To track all earnings releases for Texas Instruments <a href="https://www.benzinga.com/quote/TXN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Texas Instruments Q4 Earnings Assessment

<p><strong>Business First Bancshares</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFST#NASDAQ">BFST</a>) released its Q4 earnings on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Business First Bancshares beat estimated earnings by 35.0%, reporting an EPS of $0.66 versus an estimate of $0.49.</p>
<p>Revenue was up $17.41 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>The company beat on EPS by $0.11 in the previous quarter, leading to a 4.0% increase share price change the next day.</p>
<p>Here's a look at Business First Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.57</td>
<td>0.51</td>
<td>0.57</td>
<td>0.60</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.68</td>
<td>0.64</td>
<td>0.50</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>65.32M</td>
<td>62.96M</td>
<td>62.22M</td>
<td>62.47M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>66.90M</td>
<td>66.19M</td>
<td>60.92M</td>
<td>60.17M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Business First Bancshares <a href="https://www.benzinga.com/quote/BFST/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Business First Bancshares Earnings Review: Q4 Summary

<p><strong>Covenant Logistics Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVLG#NYSE">CVLG</a>) released its Q4 earnings on Thursday, January 23, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Covenant Logistics Gr missed estimated earnings by 0.0%, reporting an EPS of $0.49 versus an estimate of $0.49.</p>
<p>Revenue was up $3.35 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company missed on EPS by $0.0 in the last quarter, resulting in a 0.0% increase share price change the following day.</p>
<p>Here's a look at Covenant Logistics Gr's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.55</td>
<td>0.49</td>
<td>0.39</td>
<td>0.52</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.55</td>
<td>0.52</td>
<td>0.42</td>
<td>0.54</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>299.81M</td>
<td>292.63M</td>
<td>273.30M</td>
<td>281.75M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>258.60M</td>
<td>287.50M</td>
<td>278.76M</td>
<td>273.99M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Covenant Logistics Gr <a href="https://www.benzinga.com/quote/CVLG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Covenant Logistics Gr Q4 Earnings

In a report released today, Dae Gon Ha from Stifel Nicolaus maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report), with a price t...

Soleno Therapeutics (SLNO) Receives a Buy from Stifel Nicolaus

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) on November 6 and set a price target ...

Positive Outlook for Soleno Therapeutics: Buy Rating Based on Anticipated FDA Approval and Strong Cash Position

Soleno Therapeutics ( ($SLNO) ) has released its Q3 earnings. Here is a breakdown of the information Soleno Therapeutics presented to its investors...

Soleno Therapeutics Reports Q3 Progress and Financials

Soleno Therapeutics slides after FDA review extension of its Prader-Willi syndrome treatment

Soleno Therapeutics (SLNO) announced that the U.S. Food and Drug Administration, FDA, has extended the review period for the New Drug Application, ...

Soleno Therapeutics announces U.S.. FDA to ended review period for NDA

Welcome to this week's installment of "The Short Interest Report" – The Fly's weekly recap of short interest trends among some of the most widely f...

Short Report: Bears look to fade Archer Aviation ascent

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Soleno Therapeutics (SLNO – Research Report), with a pric...

Confident Buy Rating on Soleno Therapeutics Amidst Imminent FDA Approval and Strong Valuation

Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me

Soleno Therapeutics enters into $200M debt financing with Oxford Finance

Catalyst Watch: Labor pains for Amazon & Starbucks, Nasdaq call-up for MicroStrategy and Pony AI ratings

ACHR

ALMS

AMCX

AMTM

AMZN

AXON

CRVL

DNTH

DXST

GALT

GLATF

GOEV

ILMN

KELYA

LMNR

NDSN

NMRA

NUKK

PLTR

PONY

QMCO

QRVO

QUBT

RYTM

SAVA

SBUX

SMCI

WBTN

WDAY

Press Releases

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Comments

Soleno Therapeutics

매도 수량

Soleno Therapeutics (NASDAQ:SLNO) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌